Published in Biotech Business Week, April 26th, 2004
"Tollefson, a Distinguished Visiting Lilly Research Scholar and Clinical professor of Psychiatry at the Indiana University School of Medicine, brings to Cortex's Board vast experience in neuroscience and significant business accomplishments at Eli Lilly & Company, playing a key strategic role in their blockbuster antidepressant and antipsychotic drugs Prozac and Zyprexia, respectively," stated Roger G. Stoll, chairman, president and CEO of Cortex. The appointment increases the number of directors on the company's Board from six to seven.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.